Tungstophosphoric acid (H3PW12O40) as a heterogeneous inorganic catalyst. Activation of hexamethyldisilazane (HMDS) by tungstophosphoric acid for efficient and selective solvent-free O-silylation reactions
Tungstophosphoric acid (H3PW12O40) effectively activates hexamethyldisilazane for the selective silylation of primary, secondary, tertiary and phenolic hydroxy groups under solvent-free conditions at 55–60 °C.
Silica Triflate as a New, Efficient, and Reusable Reagent for the Chemoselective Silylation of Alcohols and Phenols and Deprotection of Silyl Ethers
作者:F. Shirini、K. Marjani、H. Taherpour Nahzomi、M. A. Zolfigol
DOI:10.1080/10426500701567046
日期:2007.12.24
Silica triflate was easily prepared via reaction of silica gel and trifluoromethane sulfonyl chloride at room temperature. This compound can be employed as an efficient and reusable reagent for the chemoselective silylation of alcohols and phenols in solution and under solvent-free conditions. This reagent also effectively catalyzed the deprotection of silyl ethers in refluxing methanol.
[EN] PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS<br/>[FR] DÉRIVÉS DE PHÉNYLÉTHYLPYRIDINE COMME INHIBITEURS DE PDE4
申请人:CHIESI FARMA SPA
公开号:WO2014086852A1
公开(公告)日:2014-06-12
The invention relates to novel compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
[EN] HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DÉRIVÉS HÉTÉROARYLE POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
申请人:CHIESI FARMA SPA
公开号:WO2015082616A1
公开(公告)日:2015-06-11
The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.